BriaCell Therapeutics Corp. Revenue and Competitors
Estimated Revenue & Valuation
- BriaCell Therapeutics Corp.'s estimated annual revenue is currently $4M per year.
- BriaCell Therapeutics Corp.'s estimated revenue per employee is $155,000
Employee Data
- BriaCell Therapeutics Corp. has 26 Employees.
- BriaCell Therapeutics Corp. grew their employee count by 8% last year.
BriaCell Therapeutics Corp.'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | Head Quality Assurance | Reveal Email/Phone |
5 | Clinical Operations Manager | Reveal Email/Phone |
6 | Senior Scientist | Reveal Email/Phone |
7 | Scientist | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | Senior Research Associate | Reveal Email/Phone |
10 | Senior Scientist | Reveal Email/Phone |
BriaCell Therapeutics Corp. Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is BriaCell Therapeutics Corp.?
ABOUT BRIACELL BriaCell (TSXV: BCT) (OTCQB: BCTXF) is a clinical stage immuno-oncology focused biotechnology company developing the first off the shelf personalized immunotherapy for cancer. The company is conducting a Phase IIa clinical trial for its lead product candidate, Bria-IMT™, in advanced breast cancer along with the co-development of BriaDX™, its companion diagnostic. Additionally, there is an FDA approved combination study of Bria-IMT™ with pembrolizumab or ipilimumab for patients with advanced breast cancer previously treated with Bria-IMT™. Moreover, BriaCell is developing Bria-OTS™, the first “off the shelf†personalized treatment for advanced stage Breast Cancer. BriaCell's small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases. For additional information on BriaCell, please visit our website: http://briacell.com/
keywords:N/A
N/A
Total Funding
26
Number of Employees
$4M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Berkeley
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.4M | 26 | 18% | N/A |
#2 | $2.6M | 26 | 18% | N/A |
#3 | $3M | 26 | 0% | N/A |
#4 | $4M | 26 | -4% | $18M |
#5 | $4M | 26 | 0% | N/A |